Vesugen

The report described improved clinical and instrumental measures of penile arterial blood flow after Vezugen monotherapy. The English title and abstract describe different clinical framing, so the record requires manual source-language review.

A 32-person study of Pinealon and Vesugen in participants with polymorbidity and organic brain syndrome reported changes in biological-age indicators, but also reported pro-oxidant activity and reduced circulating CD34-positive hematopoietic markers. The small sample, mixed compounds, unclear control methods, surrogate endpoints, and concerning laboratory signals prevent anti-aging, geroprotective, or safety claims, and prevent attribution to either compound alone.

A study of professional truck drivers and metal-worker controls reported the best psychoadaptive effect with combined Pinealon and Vesugen. Combination exposure, occupational confounding, unclear treatment allocation, and subjective endpoints prevent attribution of this result to either compound alone.

EDR and related short peptides partially protected induced neurons from age-associated cellular changes and influenced dendritic measures.

The report described changes in pial microvascular density and oxygenation after exposure to a vascular peptide bioregulator.

Repeated-course effects on cerebral microcirculation were reported in rats.

The vascular peptide bioregulator was associated with increased pial microvascular density in aged rats.

The study reported age-dependent microcirculatory changes after a course of vascular peptide bioregulator.

Vesugen/KED influenced Ki-67-related endothelial-cell proliferation in aging cell models and was modeled interacting with promoter DNA. This is mechanistic evidence, not controlled clinical cardiovascular evidence.

An in-vitro study reported effects of EDR and KED on serotonin expression in brain-cortex cells. This cell finding does not establish human neurogenesis, cognitive benefit, or a validated clinical mechanism, and cannot be assigned to KED/Vesugen alone.

An in-vitro stem-cell study reported effects of KED and AEDG on aging human oral stem cells. This cell finding does not establish human anti-aging benefit or clinical tissue specificity.

A 2025 in-vitro study reported effects of KED and other short peptides on neuronal differentiation and cell senescence. This cell finding does not establish human neurogenesis, anti-aging, or clinical benefit.

A laboratory study reported effects of KED/Vesugen on tissue-specific cell differentiation markers. This cell finding does not establish vascular rejuvenation, reversal of atherosclerosis, or clinical benefit.

Current Drugs@FDA name searches performed for this frozen package did not identify approved drug products under the names AHK-Cu, FOXO4-DRI, Pinealon, or Mechano Growth Factor. A negative name search does not exclude differently named products but establishes that no approval was identified under these research names.

Cardiogen, Cortagen, Pinealon, and Vesugen were not identified in FDA's current 503A nominated bulk-drug-substance category document, updated May 14, 2026. Absence from that document is not approval, a safety determination, or authorization to compound.

No modern registered interventional development program for Cardiogen, Cortagen, Pinealon, or Vesugen was identified in the reviewed ClinicalTrials.gov searches.

The paper’s tables identify Crystagen as EDP (Glu-Asp-Pro) and discuss transport of ultrashort peptides.

The article summarizes KED (Lys-Glu-Asp) research involving neuronal differentiation and Alzheimer disease-related models.

The review identifies AED as Cartalax and summarizes short-peptide gene-regulatory work. The literature is predominantly mechanistic/preclinical and cannot establish clinical disease-modifying efficacy.

The publication describes KED (Lys-Glu-Asp) as a short vasoregulatory peptide and summarizes proposed endothelial mechanisms. It does not provide modern pivotal cardiovascular-outcomes evidence.